RAS Blocker Safety Calculator
This tool helps you understand your risk of complications when taking ACE inhibitors or ARBs. Enter your health data to see if you're at risk for high potassium levels or kidney injury. Based on evidence from major clinical trials.
Risk Assessment Results
Why ACE Inhibitors and ARBs Are Often Confused
Both ACE inhibitors and ARBs lower blood pressure and protect the kidneys, especially in people with diabetes or heart failure. They target the same system in your body-the renin-angiotensin system-but they do it in different ways. That’s why many patients and even some doctors assume they’re interchangeable. They’re not. And mixing them can be dangerous.
ACE inhibitors like lisinopril and enalapril stop your body from making angiotensin II, a chemical that tightens blood vessels and raises blood pressure. ARBs like losartan and valsartan don’t stop its production-they block its action at the receptor level. Think of it like this: ACE inhibitors turn off the faucet that fills a bucket; ARBs leave the faucet on but lock the bucket so the water can’t fill it. Both reduce pressure, but the way they work changes how your body responds.
The Real Difference: Side Effects That Matter
If you’ve been on an ACE inhibitor and developed a dry, nagging cough, you’re not alone. About 1 in 8 people get it. That cough isn’t just annoying-it’s the reason many stop taking the drug. It’s caused by bradykinin, a substance that builds up when ACE is blocked. ARBs don’t cause this buildup, so only about 1 in 25 patients on ARBs report coughing. That’s a big deal if you’re trying to stick with your medication long-term.
Angioedema-swelling of the face, lips, or throat-is rare but serious. It happens in about 0.1% to 0.7% of ACE inhibitor users. For ARBs, it’s even rarer: 0.1% to 0.2%. If you’ve had angioedema on an ACE inhibitor, you’re not supposed to take an ARB. The risk isn’t zero, and doctors avoid it.
Both drugs can raise potassium and hurt kidney function, especially in older adults or those with existing kidney disease. But here’s what most people don’t realize: ACE inhibitors have stronger proof of saving lives in heart failure. Studies show they cut death risk by 23% in heart failure patients with reduced pumping ability. ARBs? Around 15%. That’s why guidelines still put ACE inhibitors first for heart failure, even if ARBs are easier to tolerate.
Combining ACE Inhibitors and ARBs: Why It’s a Bad Idea
You might think, "If one is good, two must be better." That’s the myth that got a lot of people into trouble. In the early 2000s, doctors tried combining them hoping for extra kidney protection, especially in diabetic patients with protein in their urine. The results were alarming.
The ONTARGET trial in 2008 followed over 25,000 high-risk patients. One group got ramipril (an ACE inhibitor). Another got telmisartan (an ARB). A third got both. The combo group had no better survival rate. No fewer heart attacks. No slower kidney decline. But they had twice the risk of dangerously high potassium levels and an 80% higher chance of acute kidney injury. Some even needed dialysis.
Since then, every major guideline has warned against it. The American Heart Association, the American College of Cardiology, and the European Society of Cardiology all say: don’t combine them. Not for hypertension. Not for kidney disease. Not even for stubborn proteinuria. The risks outweigh any tiny benefit.
Real-world data backs this up. A 2023 survey of 317 primary care doctors found that 89% had stopped prescribing the combo after seeing the evidence. One nephrologist reported discontinuing it in 87% of her diabetic kidney patients because of high potassium or sudden drops in kidney function.
When Is a Switch Better Than a Combo?
If you can’t tolerate an ACE inhibitor because of cough or swelling, switching to an ARB is the standard next step. It’s safe, effective, and avoids the worst side effects. But don’t do it cold turkey. Experts recommend waiting at least 4 weeks after stopping an ACE inhibitor before starting an ARB. Why? Because even after you stop the drug, its effects linger in your system. Starting the other too soon can spike your potassium or crash your blood pressure.
And if you need stronger blood pressure control or kidney protection after maxing out one drug? Don’t add the other. Add a low-dose diuretic like hydrochlorothiazide or a mineralocorticoid antagonist like spironolactone. Studies show spironolactone cuts proteinuria by 30-40% without the same risks as combining ACE and ARB drugs.
Monitoring Is Non-Negotiable
Whether you’re on one or the other, you need regular blood tests. Your doctor should check your potassium and creatinine (a marker of kidney function) 1-2 weeks after starting or changing the dose. After that, every 3 months is standard.
High potassium doesn’t always cause symptoms, but when it does, you might feel weak, dizzy, or get an irregular heartbeat. That’s not something to wait on. If your potassium goes above 5.5 mmol/L, your doctor may pause your medication and prescribe a potassium binder like patiromer or sodium polystyrene sulfonate.
Same goes for kidney function. A 20% drop in your eGFR (estimated glomerular filtration rate) in the first month isn’t always bad-it can mean your kidneys are adjusting. But if it keeps falling, or if your creatinine rises above 30% from baseline, you need a reevaluation. This is especially true if you’re dehydrated, on NSAIDs like ibuprofen, or have heart failure.
What About Newer Alternatives?
There’s a reason ARNIs (angiotensin receptor-neprilysin inhibitors) like sacubitril/valsartan are replacing ACE inhibitors in many heart failure cases. They combine ARB action with a compound that boosts protective hormones, leading to better survival and fewer hospitalizations. The FDA approved them for heart failure with reduced ejection fraction in 2015, and they’re now first-line in many guidelines.
For hypertension, newer drugs like direct renin inhibitors (aliskiren) were tested, but they showed more harm than benefit when combined with ACE inhibitors or ARBs. The FDA pulled the plug on those combos in 2012.
Right now, the future of RAS blockade isn’t about mixing old drugs-it’s about using the right one at the right dose and adding safer partners like SGLT2 inhibitors (for diabetes and kidney protection) or finerenone (a non-steroidal mineralocorticoid blocker). These are the real next steps, not combining ACE and ARB drugs.
Market Trends and Real-World Use
In 2023, ACE inhibitors still led in prescriptions-58% of all RAS blocker starts in the U.S. Lisinopril alone was prescribed over 22 million times. ARBs like losartan followed close behind at 42%. But the trend is shifting. More people are switching from ACE inhibitors to ARBs because of side effects, not because ARBs are stronger.
There was a scare in 2018-2020 when some ARBs were recalled due to cancer-causing impurities. That shook confidence, but manufacturers fixed the problem. By late 2023, most ARBs on the market were clean and safe.
Even in Europe, where a few fixed-dose combos of ACE + ARB were approved for heart failure, they’re not used for high blood pressure. In the U.S., they’re still banned. The message is clear: if you’re not in a clinical trial, don’t mix them.
What’s Next? The Research Still Evolving
A trial called FINE-REWIND, running from 2024 to 2028, is testing whether tiny, half-doses of both drugs together might be safe and helpful for diabetic kidney disease. Early results aren’t due until late 2026. Until then, the evidence says: avoid the combo.
The bottom line? ACE inhibitors and ARBs are powerful tools. But they’re not interchangeable, and combining them is risky. If you’re on one and it’s working, stick with it. If you have side effects, talk to your doctor about switching-not adding. Your kidneys and your heart will thank you.
Can I take an ACE inhibitor and an ARB together for better blood pressure control?
No. Combining ACE inhibitors and ARBs does not provide meaningful benefits in lowering heart attacks, strokes, or death. Instead, it doubles your risk of dangerously high potassium levels and triples your chance of sudden kidney injury. Major guidelines from the American Heart Association and the American College of Cardiology strongly advise against this combination in all but rare research settings.
Why do some people get a cough with ACE inhibitors but not with ARBs?
ACE inhibitors block the enzyme that breaks down bradykinin, a substance that causes inflammation and irritation in the airways. This buildup leads to a dry, persistent cough in about 10-15% of users. ARBs don’t affect bradykinin, so cough is rare-only 3-5% of people on ARBs report it. If you develop a cough on an ACE inhibitor, switching to an ARB usually resolves it.
Is it safe to switch from an ACE inhibitor to an ARB?
Yes, switching is a common and safe strategy if you can’t tolerate an ACE inhibitor due to cough or swelling. However, you should wait at least 4 weeks after stopping the ACE inhibitor before starting the ARB. This prevents overlapping effects that could cause low blood pressure or a sudden spike in potassium. Always do this under your doctor’s supervision.
Do ACE inhibitors and ARBs affect kidney function the same way?
Both can reduce kidney filtration in the short term, which is normal and often protective in patients with proteinuria. But long-term, they carry similar risks of acute kidney injury-especially in people with existing kidney disease, heart failure, or dehydration. The key difference is that combining them increases this risk by 80%, making kidney damage much more likely. Monitoring creatinine and potassium every 3 months is essential for anyone on either drug.
What should I do if I’m currently taking both an ACE inhibitor and an ARB?
Stop taking both immediately and contact your doctor. Taking them together increases your risk of life-threatening high potassium and sudden kidney failure. Your doctor will likely choose one-either the ACE inhibitor or the ARB-based on your condition and side effects. You may need a short hospital stay if your potassium is very high or your kidney function has dropped sharply.
Are there safer alternatives to ACE inhibitors and ARBs for kidney protection?
Yes. For patients with diabetes or kidney disease, SGLT2 inhibitors like empagliflozin and dapagliflozin have been shown to reduce kidney decline and heart failure hospitalizations more effectively than adding ARBs. Mineralocorticoid receptor antagonists like finerenone also offer kidney protection with less risk of high potassium than ACE/ARB combos. These are now preferred in modern guidelines over combining two RAS blockers.
8 Comments
I was on lisinopril for years and the cough was unbearable
It felt like my throat was lined with sandpaper 24/7
Switched to losartan and it vanished overnight
No more midnight coughing fits or ruined sleep
Why do doctors still push ACE inhibitors first if this is so common?
The notion that combining these drugs offers additive benefit is a dangerous fallacy perpetuated by pharmaceutical marketing and misguided clinical optimism. The ONTARGET trial laid this to rest with statistical rigor. To prescribe both is not merely suboptimal-it is negligent. The British National Health Service has long held this position, and it is high time American clinicians caught up.
Honestly why even talk about this anymore the data is old and everyone knows not to mix them
I work in a rural clinic and see this all the time
Patients come in with both scripts and say their old doctor told them it was fine
It’s heartbreaking because they’re not being reckless-they’re just trusting someone who didn’t know better
Education needs to go beyond guidelines and into the waiting rooms
You guys are killing it with this breakdown!!!
Seriously, this is the kind of info that saves lives
My dad was on both for a while and ended up in the ER with potassium at 6.2
He’s now on spironolactone + SGLT2i and his numbers are perfect
Don’t be afraid to ask your doc about alternatives-your kidneys will thank you!!
Also, if you’re on ARBs and feel weirdly tired? Check your K+-it’s sneaky!
The pharmacodynamic divergence between ACE inhibition and AT1 receptor blockade is well-documented in the renin-angiotensin-aldosterone system literature. The bradykinin-mediated cough is a class-specific phenomenon attributable to ACE's role in kinin metabolism, whereas ARBs preserve neutral endopeptidase activity. Consequently, the concomitant administration of both agents results in synergistic hyperkalemia and a disproportionate decline in glomerular filtration rate, as evidenced by the increased incidence of acute kidney injury in the ONTARGET cohort. Adherence to ESC/ACC guidelines is not optional-it is standard of care.
People treat medicine like a menu
You pick what feels good
But the body doesn't care about your comfort
It cares about balance
And when you mess with the RAS system you're not fixing anything
You're just trading one problem for another
And calling it progress
Thank you for writing this-it’s so clear and practical.
One thing I’d add: if you’re switching from ACE to ARB, don’t just wait four weeks-get your baseline creatinine and potassium checked before you start the new one.
And if you’re diabetic, ask about finerenone or an SGLT2 inhibitor-they’re game-changers for kidney protection without the potassium risk.
Also, please, please, please avoid NSAIDs while on either drug. Ibuprofen is the silent killer here.